Many of those living with HIV face a new life-threatening challenge: cancer

Unique clinical trial addresses important questions about treating cancer in those with HIV

2011-06-07

(Press-News.org) CHICAGO – As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others. The alarming uptick in cancer rates highlights the critical need to understand how to treat tumors in people taking highly active anti-retroviral therapy (HAART) for HIV. Given what is known about HAART drug interactions, can newer targeted cancer therapies be given safely to patients with HIV?

To explore potential interactions between HAART and the newer cancer drugs, the AIDS Malignancy Consortium (AMC), a National Cancer Institute (NCI)-supported clinical trials group founded in 1995 to support innovative trials for AIDS-related cancers, has conducted the first of a planned series of studies. John Deeken, M.D., a research physician at Georgetown Lombardi Comprehensive Cancer Center and national chairman of the study, presented the findings today during a poster session at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

He says these early results already have the potential to change the way that cancer is treated in HIV patients.

"Up to this point, oncologists have not had much information about treating cancer in people taking HAART," says Deeken. "We're basically at square one because people with HIV usually are not included in cancer clinical trials. They're excluded because physicians are worried about causing further immune suppression in HIV patients, and because HAART drugs are notorious for causing drug-drug interactions and serious side effects."

The first drug being studied is sunitinib. Sunitinib (Sutent®) may stop the growth of cancer cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. However, agents in the HAART cocktail are thought to affect the same enzymes involved in sunitinib metabolism.

The AMC chose to study sunitinib because this oral medication was approved by the Food and Drug Administration to treat kidney cancer, which is occurring at an increasing rate among HIV patients, and the drug is being studied in other cancer types that also affect HIV patients, such as lung and liver cancers.

Safety was examined separately for two groups within the phase I study. Group one included those whose HAART combination did not include ritonavir, while patients in group two were taking a ritonavir-based protease inhibitor HAART cocktail.

Between August 2009 and April 2011, a total of 19 patients were enrolled, treated, and completed at least one cycle of therapy. Sunitinib (50mg/day) was well tolerated in patients in group one – those taking non-ritonavir based HAART regimens. Patients treated with sunitinib who were in group two, those taking the ritonavir-based therapy, experienced more side effects including higher rates of neutropenia (compared to those reported on phase III studies of sunitinib).

"Already, we have important information that can impact treatment," says Deeken. "When the trial is complete, we may have data to recommend that patients take different dosages of sunitinib based on what HAART cocktail they are taking. We also found that patients could keep taking their HIV medications safely, and that sunitinib did not affect the HIV disease status of patients in either group."

"Our HIV disease is now frequently being well controlled with HAART medications, but we are still having multiple medical problems including getting cancer earlier and more frequently," says James Weihe, a community representative for the AIDS Malignancy Consortium. "I am 60 years old and have been diagnosed with 3 minor cancers and 2 major cancers within the last 2 years. Frequently we are rejected from clinical trials just because we are HIV positive. Dr. Deeken and the work his colleagues are doing give us new hope. Their research shows that we can be included in cancer research trials if the dosages of the medications are adjusted to avoid drug-drug interactions and other side effects."

"The NCI has called for clinical trials criteria to include people with HIV though the adoption of these criteria has been slow," says Deeken. "Here we are, years after many new and effective anti-cancer treatments have been identified and we know so little about using these drugs in people who are also on therapy for their HIV. While the need for caution is understandable, it may be scientifically unjustified as well as fundamentally unfair to exclude patients with HIV from clinical trials." ### The AMC study is sponsored by the National Cancer Institute under a Clinical Trials Agreement with Pfizer, Inc who provided the sunitinib.

About Georgetown Lombardi Comprehensive Cancer Center Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Georgetown Lombardi is one of only 40 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.

About Georgetown University Medical Center Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2009-2010, GUMC accounted for nearly 80 percent of Georgetown University's extramural research funding.

ELSE PRESS RELEASES FROM THIS DATE:

New strategy to attack tumor-feeding blood vessels

2011-06-07

Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours. The research team from the institute's Molecular Genetics of Cancer and Cancer and Haematology divisions found that for anti-cancer therapies that target tumour blood vessels to work the death- inducing molecule Bim is required. The finding could lead to improved anti-cancer treatments that are based on a two- or three-pronged attack on both the tumour and its blood supply. The research will be published online in the Journal of Experimental ...

Singapore researchers invent broadband graphene polarizer

2011-06-07

Researchers at the National University of Singapore have invented a graphene-based polarizer that can broaden the bandwidth of prevailing optical fibre-based telecommunication systems. The graphene research team, led by Professor Kian Ping Loh at the National University of Singapore, invented an ultra-slim broadband polarizer that uses graphene, a single-atomic-layer crystallized carbon, to convert light beam into polarized light. This is the first experimental demonstration of using graphene as an ultrathin waveguide to couple and modulate light. Light modulation by ...

Research creates nanoparticles perfectly formed to tackle cancer

2011-06-07

Researchers from the University of Hull have discovered a way to load up nanoparticles with large numbers of light-sensitive molecules to create a more effective form of photodynamic therapy (PDT) for treating cancer. Photodynamic therapy uses molecules which, when irradiated with light, cause irreparable damage to cells by creating toxic forms of oxygen, called reactive oxygen species. Most PDT works with individual light-sensitive molecules – but the new nanoparticles could each carry hundreds of molecules to a cancer site. A number of different light-sensitive molecules ...

Molecular movements could lead to new way to treat cancer

2011-06-07

Work by researchers at Queen Mary, University of London could point to a new way to treat aggressive types of cancer. The scientists have found that a molecule called Met is responsible for stimulating the growth and spread of cancer because it is relocating to the wrong part of the cell. Experiments in the lab suggest that moving Met molecules from the inside of the cell to the cell surface could halt the growth of cancer cells and even cause tumours to shrink. Met molecules are involved in the growth of cells in the human body but they are usually only active in ...

Methane gas from cows -- the proof is in the poo

2011-06-07

Scientists could have a revolutionary new way of measuring how much of the potent greenhouse gas methane is produced by cows and other ruminants, thanks to a surprising discovery in their poo. Researchers from the University of Bristol and the Teagasc Animal and Grassland Research Centre in Ireland, have found a link between methane production and levels of a compound called archaeol in the faeces of several fore-gut fermenting animals including cows, sheep and deer. The compound could potentially be developed as a biomarker to estimate the methane production from ...

Kinder, gentler video games may actually be good for players

2011-06-07

COLUMBUS, Ohio – While violent video games may lead to more aggression and anger in players, a new study shows that the opposite is also true: relaxing video games can make people happier and more kind. "With all the evidence about the dangers of violent video games, it's good to know that game players can choose games that will provide a positive experience," said Brad Bushman, co-author of the study and professor of communication and psychology at Ohio State University. Bushman has conducted many studies showing the bad effects of violent games, especially on teens ...

Weizmann Institute Observatory captures images of a new supernova

2011-06-07

Exploding stars are the 'factories' that produce all the heavy elements found, among other places, in our bodies. In this sense, we are all stardust. These exploding stars – supernovae – are highly energetic events that can occasionally light up the night sky. Such an explosion generally involves disruption in the balance between gravity – which pulls the star's material inward – and the thermonuclear reaction at the star's core – which heats it and pushes it outward. Certain types of stars that go in this way have a much bigger mass (10-100 times) and are much younger ...

Bakon Vodka Signs with Southern Wine & Spirits and Expands Relationship with Republic National As Sales Approach One Million Dollars

2011-06-07

The world's first 'meat-flavored spirit', Bakon Vodka (www.bakonvodka.com), today announced a new partnership with the number one distributor in the United States, Southern Wine & Spirits. Bakon Vodka has also strategically expanded its partnerships with Republic National Distributing Company and California's BevMo! stores to increase product accessibility as a result of growing demand for the bacon vodka infusion. Currently available in 32 states, the acclaimed and award-winning spirit is expected to be available in all 50 states and break sales of one million dollars ...

Surgically shrinking the stomach when conservative weight-loss treatments fail

2011-06-07

The treatment of obesity still needs improvement. In the current issue of Deutsches Ärzteblatt International, Norbert Runkel and colleagues present a new, interdisciplinary S3 guideline entitled "Bariatric Surgery" (Dtsch Arztebl Int 2011; 108[20]: 341𔃄). One in two persons in Germany is overweight, and every fifth one is obese. Conservative treatment is considered to have been exhausted when it fails to bring about a 10% to 20% loss of weight in one year in a patient whose initial body-mass index was between 35 and 40 kg/m2. In this situation, bariatric surgery ...

Hard or soft: At the touch of a button

2011-06-07

This world-first has its origins in Hamburg. Jörg Weißmüller, a materials scientist at both the Technical University of Hamburg and the Helmholtz Center Geesthacht, has carried out research on this groundbreaking development, working in cooperation with colleagues from the Institute for Metal Research in Shenyang, China. The 51-year-old researcher from the Saarland referred to his fundamental research, which opens the door to a multitude of diverse applications, as "a breakthrough in the material sciences". The new metallic high-performance material is described by Prof. ...

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Many of those living with HIV face a new life-threatening challenge: cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: